Adaptive Biotechnologies Corp Share Price Today: Live Updates & Key Insights

Adaptive Biotechnologies Corp share price today is $22.67, up -0.18%. The stock opened at $22.485 against the previous close of $22.31, with an intraday high of $22.74 and low of $21.87.

Adaptive Biotechnologies Corp Share Price Chart

Adaptive Biotechnologies Corp

us-stock
To Invest in {{usstockname}}
us-stock

Adaptive Biotechnologies Corp Share Price Performance

$22.67 -0.0018(-0.18%) ADPT at 27 Jul 2026 01:51 PM Diagnostics & Research
Lowest Today 21.87
Highest Today 22.74
Today’s Open 22.485
Prev. Close 22.31
52 Week High 23.15
52 Week Low 9.96
Day’s Range: Low 21.87 High 22.74
52-Week Range: Low 9.96 High 23.15
1 day return -
1 Week return +1.96
1 month return +6.44
3 month return +56.86
6 month return +16.45
1 year return +110.08
3 year return +176.37
5 year return -39.54
10 year return -

Adaptive Biotechnologies Corp Institutional Holdings

Viking Global Investors LP 4.69

BlackRock Inc 2.08

Vanguard Group Inc 1.76

Vanguard Capital Management, LLC 0.95

Westfield Capital Management Company, L.P. 0.85

Vanguard Total Stock Mkt Idx Inv 0.76

Vanguard Portfolio Management, LLC 0.70

Amvescap Plc. 0.70

iShares Russell 2000 ETF 0.62

Wellington Management Company LLP 0.60

Geode Capital Management, LLC 0.57

Lord, Abbett & Co LLC 0.55

The Goldman Sachs Group Inc 0.51

State Street Corp 0.50

Ameriprise Financial Inc 0.47

BNP Paribas Investment Partners SA 0.42

ARK Investment Management LLC 0.33

Fred Alger Management, LLC 0.32

ARK Genomic Revolution ETF 0.32

ARK Genomic Revolution 0.31

Arrowstreet Capital Limited Partnership 0.31

D. E. Shaw & Co LP 0.31

Delaware Management Holdings Inc 0.29

Driehaus Capital Management LLC 0.27

Vanguard Small Cap Index 0.27

Xtrackers MSCI World Swap ETF 1C 0.25

Alger Small Cap Focus Composite 0.23

Alger Small Cap Focus I 0.23

Fidelity Small Cap Index 0.23

iShares Russell 2000 Growth ETF 0.22

Vanguard Institutional Extnd Mkt Idx Tr 0.22

Lord Abbett Developing Growth A 0.22

BNP Paribas US Small Cap ClassicC 0.20

Invesco Main Street Small Cap R6 0.19

Oberweis Micro-Cap Growth 0.19

Invesco Small Cap Core 0.18

iShares Biotechnology ETF 0.17

Amova ARK Pstv Chg Innovt P JPY Acc 0.17

T. Rowe Price Integrated US SmCapGrEq 0.17

T. Rowe Price Integrated US Sm Gr Eq 0.17

Adaptive Biotechnologies Corp Market Status

Strong Buy: 3

Buy: 4

Hold: 1

Sell: 0

Strong Sell: 0

Adaptive Biotechnologies Corp Fundamentals

Market Cap 3570.59 M

PB Ratio 16.2382

PE Ratio 0.0

Enterprise Value 3429.88 M

Total Assets 512.74 M

Volume 2819965

Adaptive Biotechnologies Corp Company Financials

Annual Revenue FY25:276976000 277.0M, FY23:179690000 179.7M, FY22:185308000 185.3M, FY21:154344000 154.3M, FY20:98382000 98.4M

Annual Profit FY25:205617000 205.6M, FY23:107164000 107.2M, FY22:127399000 127.4M, FY21:105043000 105.0M, FY20:75852000 75.9M

Annual Net worth FY25:-59499000 -59.5M, FY23:-195937000 -195.9M, FY22:-142464000 -142.5M, FY21:-205611000 -205.6M, FY20:-139637000 -139.6M

Quarterly Revenue Q1/2026:70874000 70.9M, Q4/2025:71681000 71.7M, Q3/2025:93973000 94.0M, Q2/2025:58879000 58.9M, Q1/2025:52443000 52.4M

Quarterly Profit Q1/2026:52166000 52.2M, Q4/2025:53457000 53.5M, Q3/2025:75816000 75.8M, Q2/2025:40880000 40.9M, Q1/2025:35464000 35.5M

Quarterly Net worth Q1/2026:-20033000 -20.0M, Q4/2025:-13579000 -13.6M, Q3/2025:9546000 9.5M, Q2/2025:-25614000 -25.6M, Q1/2025:-29852000 -29.9M

About Adaptive Biotechnologies Corp & investment objective

Company Information Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Organisation Diagnostics & Research

Employees 624

Industry Diagnostics & Research

CEO Mr. Chad M. Robins M.B.A.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Adaptive Biotechnologies Corp FAQs

What is the share price of Adaptive Biotechnologies Corp today?

The current share price of Adaptive Biotechnologies Corp is $22.67.

Can I buy Adaptive Biotechnologies Corp shares in India?

Yes, Indian investors can buy Adaptive Biotechnologies Corp shares by opening an international trading and demat account with Motilal Oswal.

How to buy Adaptive Biotechnologies Corp shares in India?

You can easily invest in Adaptive Biotechnologies Corp shares from India by:

Can I buy fractional shares of Adaptive Biotechnologies Corp?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Adaptive Biotechnologies Corp?

Adaptive Biotechnologies Corp has a market cap of $3570.59 M.

In which sector does Adaptive Biotechnologies Corp belong?

Adaptive Biotechnologies Corp operates in the Diagnostics & Research sector.

What documents are required to invest in Adaptive Biotechnologies Corp stocks?

To invest, you typically need:

What is the PE and PB ratio of Adaptive Biotechnologies Corp?

The PE ratio of Adaptive Biotechnologies Corp is N/A and the PB ratio is 16.24.